HTR4
5-hydroxytryptamine receptor 4
As of the edition of 20 October 2026, HTR4 (5-hydroxytryptamine receptor 4, UniProt Q13639) has 18 drugs tested at it and 21 companies on the list, 12 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13639
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Digestive system; Mental health; Hormones; Nervous system; Nutrition and metabolism; Cancer; Heart and blood vessels; Chemically induced
- Registered trials of its drugs
- 129
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 6 |
| Stopped | 4 |
| Withdrawn from market | 2 |
| Total | 18 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Prucalopride | Marketed | Phase 4 | Ends 2028 |
| Tegaserod | Withdrawn from market | Phase 4 | none listed |
| Mosapride | Active | Phase 4 | none listed |
| Felcisetrag | Stopped | Phase 2 | none listed |
| PF-04995274 | Stopped | Phase 1 | none listed |
| Velusetrag | Active | Phase 2 | none listed |
| Cisapride | Withdrawn from market | Phase 4 | none listed |
| Naronapride | Stopped | Phase 2 | none listed |
| PRX-03140 | Went quiet | Phase 2 | none listed |
| Levosulpiride | Marketed | Phase 3 | none listed |
| Revexepride | Went quiet | Phase 2 | none listed |
| Piboserod | Went quiet | Phase 2 | none listed |
12 of 18 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 12 |
| Route B | 1 |
| Engaged | 5 |
| Undetermined | 3 |
| Total on the list | 21 |
The other 18 companies at HTR4
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at HTR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.